Technology | August 21, 2012

Siemens syngo.PET Amyloid Plaque Software Receives FDA Clearance

New software is part of comprehensive solution for the visualization and quantification of amyloid plaques in the living brain

August 21, 2012 — Siemens Healthcare announced that its syngo.PET Amyloid Plaque proprietary software has received clearance from the U.S. Food and Drug Administration (FDA) and is now available.

Joining the new Biograph mCT positron emission tomography/computed tomography (PET/CT) scanner and PETNET Solutions’ PET radiopharmaceutical production expertise, syngo.PET Amyloid Plaque software is the third element in Siemens’ comprehensive imaging solution for the visualization and quantification of amyloid plaques – one of the necessary pathological features of Alzheimer’s disease – in the living brain.

“Our new syngo.PET software, combined with Siemens’ Biograph mCT PET/CT scanner and expertise in the production of PET radiopharmaceuticals, will provide U.S. physicians with a valuable tool for the evaluation of Alzheimer’s disease and other neurologic conditions,” said Britta Fuenfstueck, CEO of molecular imaging at Siemens Healthcare.

syngo.PET Amyloid Plaque software is designed to assist physicians with assessment of beta amyloid uptake ratios in the PET scans of patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The software registers a patient’s PET amyloid images against a reference model of a PET amyloid brain to better enable the physician to target regions of interest. Siemens’ proprietary affine registration algorithm has been demonstrated in research to have a correlation coefficient of 0.98 to the Fleisher method, a reference model that identifies six optimal zones to evaluate pathological levels of amyloid plaque burden. syngo.PET Amyloid Plaque software enables physicians to quantify uptake ratios (SUVr), which can be compared to Fleisher thresholds. Quantification of amyloid-PET images with SUVr could provide information in patients with possible mild cognitive impairment that is useful in supporting visual reads of amyloid-PET images.

syngo.PET Amyloid Plaque software is cleared for use with PET and PET/CT equipment.

For more information: www.siemens.com/alzheimers

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Intronix Technologies Developing Augmented Reality Medical Simulation for Neuromuscular Injection Procedures
News | Advanced Visualization | September 11, 2017
Canadian-based Intronix Technologies will be working with Roy Eagleson, Ph.D., professor in the Department of...
Median Technologies to Lead Roundtable on Applications of iBiopsy for Nonalcoholic Steatohepatitis
News | Advanced Visualization | September 07, 2017
September 7, 2017 — Median Technologies announced that it will lead a scientific and medical roundtable on Sept.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init